The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy
Abstract
BACKGROUND: miR‐21 has been recognized as an “onco‐microRNA” with the activity of negatively modulating the expression of tumor‐suppressor genes. However, its role in prostate cancer (CaP) has not been well‐documented. We designed this study to assess the potential function of serum miR‐21 in the progression of CaP. METHODS: Serum samples of 56 patients, including 20 patients with localized CaP, 20 with androgen‐dependent prostate cancer (ADPC), 10 with hormone‐refractory prostate cancer (HRPC), and 6 with benign prostatic hyperplasia (BPH), were collected for the measurement of miR‐21. The 10 HRPC patients were administered docetaxel‐based chemotherapy. Quantification of miR‐21 was assayed by specific TaqMan qRT‐PCR. RESULTS: Serum miR‐21 level was found to correlate to serum PSA level in patients with ADPC and HRPC, P = 0.012 and 0.049, respectively. There was no significant difference in serum miR‐21 level between BPH, localized CaP and ADPC with PSA level <4 ng/ml. Higher levels of miR‐21 were detected in patients with HRPC and ADPC with PSA level >4 ng/ml. Six of the 10 HRPC patients reached partial remission with a decreased PSA level of >50% after chemotherapy. Serum miR‐21 levels were higher in patients who were resistant to docetaxel‐based chemotherapy when compared to those sensitive to chemotherapy, P = 0.032. CONCLUSIONS: Serum miR‐21 levels are elevated in HRPC patients, especially in those resistant to docetaxel‐based chemotherapy. It may be applicable as a marker to indicate the transformation to hormone refractory disease, and a potential predictor for the efficacy of docetaxel‐based chemotherapy. Prostate 71:326–331, 2011. © 2010 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer
Taylor, D. D., & Gercel-Taylor, C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.033 · Cited by 2,288
RetractedJemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
EAU Guidelines on Prostate Cancer
Heidenreich, A., Aus, G., Bolla, M., Joniau, S., Matveev, V. B., Schmid, H. P., & Zattoni, F. (2008) · European Urology · doi:10.1016/j.eururo.2007.09.002 · Cited by 3,136
MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer
Meng, F., Henson, R., Wehbe–Janek, H., Ghoshal, K., Jacob, S. T., & Patel, T. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.022 · Cited by 2,773
MicroRNA-21 Is an Antiapoptotic Factor in Human Glioblastoma Cells
Chan, J. A., Krichevsky, A. M., & Kosik, K. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0137 · Cited by 2,557
Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate
Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S., & Redwine, E. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710083171501 · Cited by 2,451
Schetter, A. J., Leung, S. Y., Sohn, J. J., Zanetti, K. A., Bowman, E. D., Yanaihara, N., Yuen, S. T., Chan, T. L., Kwong, D. L. W., Au, G. K. H., et al. (2008) · JAMA · doi:10.1001/jama.299.4.425 · Cited by 1,578
Serum MicroRNAs Are Promising Novel Biomarkers
Gilad, S., Meiri, E., Yogev, Y., Benjamin, S., Lebanony, D., Yerushalmi, N., Benjamin, H., Kushnir, M., Cholakh, H., Melamed, N., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003148 · Cited by 1,347
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Cancer incidence and mortality in Europe, 2004
Boyle, P., & Ferlay, J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi098 · Cited by 1,217
Yan, L.-X., Huang, X.-F., Shao, Q., Huang, M.-Y., Deng, L., Wu, Q.-L., Zeng, Y.-X., & Shao, J.-Y. (2008) · RNA · doi:10.1261/rna.1034808 · Cited by 1,148
Frankel, L. B., Christoffersen, N. R., Jacobsen, A., Lindow, M., Krogh, A., & Lund, A. H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707224200 · Cited by 1,141
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene
Lu, Z., Liu, M., Stribinskis, V, Klinge, C. M., Ramos, K. S., Colburn, N. H., & Li, Y. (2008) · Oncogene · doi:10.1038/onc.2008.72 · Cited by 711
miR-21 plays a pivotal role in gastric cancer pathogenesis and progression
Zhang, Z., Li, Z., Gao, C., Chen, P., Chen, J., Liu, W., Xiao, S., & Lu, H. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.94 · Cited by 477
Quinn, M., & Babb, P. (2002) · BJU International · doi:10.1046/j.1464-410x.2002.2822.x · Cited by 446
Visone, R., & Croce, C. M. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080794 · Cited by 422
Ribas, J., Ni, X., Haffner, M., Wentzel, E. A., Salmasi, A. H., Chowdhury, W. H., Kudrolli, T. A., Yegnasubramanian, S., Luo, J., Rodriguez, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1448 · Cited by 416
Kelly, W. K., Scher, H. I., Mazumdar, M., Vlamis, V, Schwartz, M., & Fossa, S. D. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.4.607 · Cited by 385
MicroRNA involvement in hepatocellular carcinoma
Gramantieri, L., Fornari, F., Callegari, E., Sabbioni, S., Lanza, G., Croce, C. M., Bolondi, L., & Negrini, M. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00533.x · Cited by 304
Smith, D. C., Dunn, R. L., Strawderman, M. S., & Pienta, K. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1835 · Cited by 215
Yoshino, T., Shiina, H., Urakami, S., Kikuno, N., Yoneda, T., Shigeno, K., & Igawa, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0147 · Cited by 176
Slack, F. J., & Weidhaas, J. B. (2008) · New England Journal of Medicine · doi:10.1056/nejme0808667 · Cited by 170
Rosell, R., Wei, J., & Tarón, M. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.n.001 · Cited by 133
Beer, T. M., Lalani, A. S., Lee, S. J., Mori, M., Eilers, K. M., Curd, J. G., Henner, W. D., Ryan, C. W., Venner, P. M., Ruether, J. D., et al. (2008) · Cancer · doi:10.1002/cncr.23461 · Cited by 107
Oudard, S. M., Banu, E., Scotté, F., Banu, A., Médioni, J., Beuzeboc, P., Joly, F., Ferrero, J.-M., Goldwasser, F., & Andrieu, J. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm332 · Cited by 66
Zhang, H. L., Ye, D. W., Yao, X., Dai, B., Zhang, S.-L., Shen, Y., Zhu, Y., & Zhang, W. (2007) · Urologia Internationalis · doi:10.1159/000109714 · Cited by 11
Self-citation
Cited by
Clinical relevance of circulating cell-free microRNAs in cancer
Schwarzenbach, H., Nishida, N., Calin, G. A., & Pantel, K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.5 · Cited by 969
MicroRNA-Based Diagnosis and Therapy
Ho, P. T. B., Clark, I. M., & Le, L. T. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137167 · Cited by 630
MicroRNAome genome: A treasure for cancer diagnosis and therapy
Berindan‐Neagoe, I., Monroig, P. D. C., Pasculli, B., & Calin, G. A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21244 · Cited by 522
MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review
Catto, J. W. F., Alcaraz, A., Bjartell, A. S., De Vere White, R., Evans, C. P., Fussel, S., Hamdy, F. C., Kallioniemi, O., Mengual, L., Schlomm, T., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.01.044 · Cited by 469
Tanaka, Y., Kamohara, H., Kinoshita, K., Kurashige, J., Ishimoto, T., Iwatsuki, M., Watanabe, M., & Baba, H. (2013) · Cancer · doi:10.1002/cncr.27895 · Cited by 446
Metadata
- Authors
- Zhang, H., Yang, L., Zhu, Y., Yao, X., Zhang, S., Dai, B., Zhu, Y., Shen, Y., Shi, G., & Ye, D.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2010-09-14
- Volume
- 71
- Issue
- 3
- Pages
- 326-331
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2030331235
- Cited by
- 322
- References
- 29
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.